{"url_path":"/sec/apus/8-k/2026-09-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-09-11","source_url":"https://www.sec.gov/Archives/edgar/data/1894525/0001213900-26-099002-index.html","accession_number":"0001213900-26-099002","cik":"0001894525","ticker":"APUS","issuer_name":"Apimeds Pharmaceuticals US, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1894525/0001213900-26-099002-index.html","primary_entity_key":"0001894525","primary_entity_name":"Apimeds Pharmaceuticals US, Inc."},"word_count":91,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits\n\n \n\n**Exhibit No.**\n \n**Description**\n\n10.1\n \n[First Amendment to Confidential Settlement and Mutual Release Agreement, dated September 10, 2026.](ea030524501ex10-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the inline XBRL document)\n\n \n\n2\n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \nApimeds Pharmaceuticals US, Inc.\n\n \n \n\nDate: September 11, 2026\nBy:\n*/s/\nDr. Vin Menon*\n\n \nName: \nDr. Vin Menon\n\n \nTitle:\nCo-Chief Executive Officer\n\n \n\n3"}